NCT05582993 - A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 6, 2024

Primary Completion Date

April 11, 2030

Study Completion Date

April 11, 2030

Conditions

Von Willebrand Disease (VWD)

Interventions

BIOLOGICAL

Vonicog Alfa

Vonicog Alfa administered by intravenous injection.

BIOLOGICAL

ADVATE

ADVATE administered by intravenous injection.

Trial Locations (15)

10021

RECRUITING

New York - Presbyterian/Weill Cornell Medical Center, New York

10126

RECRUITING

Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin (Torino)

29425

RECRUITING

Medical University of South Carolina (MUSC), Charleston

35223

RECRUITING

University of Alabama at Birmingham, Birmingham

46202

RECRUITING

Riley Hospital for Children Indiana University Health, Indianapolis

48201

RECRUITING

Childrens Hospital of Michigan, Detroit

52242

RECRUITING

University of Iowa Hospitals & Clinics PARENT, Iowa City

55404

RECRUITING

Children's Health Care d/b/a Children's Minnesota, Minneapolis

59037

RECRUITING

Hemostase Clinique - Institut Cœur-Poumons (4eme étage aile est) Bureau 419, Lille

61614

RECRUITING

Bleeding and Clotting Disorders Institute, Peoria

69677

RECRUITING

Hopital Edouard Herriot - CHU Lyon, Lyon

80123

RECRUITING

Azienda Ospedaliera Pediatrica Santobono Pausillipon, Napoli

08901

RECRUITING

Rutgers - Robert Wood Johnson Medical School, New Brunswick

D12N512

RECRUITING

Children's Health Ireland, Dublin

634-8522

RECRUITING

Nara Medical University Hospital, Kashihara